Unfit patients even have the alternative of venetoclax moreover obinutuzumab (VO) as frontline therapy. This relies on the phase III demo that compared VO with ClbO in elderly/unfit patients.113 VO was remarkable with regard to response price and development-free survival, and had a equivalent safety profile. With this demo VO https://garrisonz222xqi3.tkzblog.com/profile